Compound
melatonin
A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen atom is replaced by a 2-(5-methoxy-1H-indol-3-yl)ethyl group. It is a hormone secreted by the pineal gland in humans.
Studied for
19 endpoints, 29 findings, from 13 papers — 17 of them found no effect.
- All-cause mortalityno detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
- Total sleep timeno detected effectGrade B, Likely. Human evidence, limited replication or design limits.
- Malondialdehyde (circulating)lowersGrade B, Likely. Human evidence, limited replication or design limits.
- Sleep onset latencylowersGrade B, Likely. Human evidence, limited replication or design limits.
- Body mass indexno detected effectGrade B, Likely. Human evidence, limited replication or design limits.
Structure
ChEBI records no single structure for this entry. That is normal for a class rather than a molecule — “a fatty acid” is a real entry with many structures and no one of them.
Loading the model…
- Class
- Organic compound
- Formula
- C13H16N2O2
- Mass
- 232.283 g/mol
- Charge
- 0
- InChIKey
- DRLFMBDRBRZALE-UHFFFAOYSA-N
- SMILES
- COc1ccc2ncc(CCNC(C)=O)c2c1
- Look it up
- ChEBIPubChemBy InChIKey
Identity from ChEBI, geometry from PubChem. Not evidence — none of it carries a grade.
What the evidence says
How to read these marks29 findings across 19 endpoints, from 13 papers, strongest first, 17 of them null.
What moved
12 findings
Decreases duration of mechanical ventilation
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“However, melatonin group demonstrated significantly lower serum HMGB-1 and NT-pro-BNP concentrations along with shorter duration of MV and less need for oxygen therapy and shorter length of NICU stay compared to control group.”
Quoted verbatim from Melatonin effects on the left ventricular function in neonates with persistent pulmonary hypertension.. - Study
- RCT
- Dose
- Oral melatonin 10 mg/kg/day for five doses, started within the first 24 h; melatonin tablets crushed, suspended in 5 mL normal saline and given by orogastric tube, in addition to standard care
- Population
- Neonates of at least 36 weeks' gestation with persistent pulmonary hypertension of the newborn (PPHN), neonatal intensive care unit, Tanta University Hospitals, Egypt; n=80 randomised and analysed (40 melatonin plus standard care, 40 placebo plus standard care); duration of mechanical ventilation was a pre-specified SECONDARY clinical outcome (primary outcome was LV function at end of therapy, with LV-GLS the principal endpoint); open to clinicians, outcome assessors blinded
Melatonin effects on the left ventricular function in neonates with persistent pulmonary hypertension.2026PMID:41954764
Decreases malondialdehyde (circulating)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“The meta-analysis indicated that melatonin supplementation considerably lowered serum MDA levels (WMD: −1.54 μmol/L, 95% CI: −2.07, −1.01) and markedly increased serum TAC levels (WMD: 0.15 mmol/L, 95% CI: 0.08, 0.22) in the melatonin-treated group versus the untreated group.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -1.54 mean difference, 95% CI -2.07 to -1.01
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
Increases total antioxidant capacity
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“Our meta-analysis indicated that melatonin intake significantly increase TAC levels (SMD: 0.87, 95% CI: 0.46, 1.28, I2 = 00.00%) compare to placebo (Table 2).”
Quoted verbatim from Effect of melatonin supplementation on cardiometabolic risk factors, oxidative stress and hormonal profile in PCOS patients: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Dose
- 3-10 mg/day oral
- Population
- women with polycystic ovary syndrome; 6 double-blind RCTs
Effect 0.87 standardised mean difference, 95% CI 0.46 to 1.28
Decreases sleep onset latency
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“The pooled SMD in healthy subjects showed that exogenous melatonin significantly decreased SOL compared to placebo.”
Quoted verbatim from Melatonergic agents influence the sleep-wake and circadian rhythms in healthy and psychiatric participants: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Healthy adult participants; pooled RCTs of exogenous melatonin vs placebo, sleep onset latency by polysomnography or actigraphy
Decreases sleep onset latency
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“Our meta-analysis demonstrated melatonin had a significant benefit in reducing sleep latency.”
Quoted verbatim from Meta-analysis: melatonin for the treatment of primary sleep disorders.. - Study
- meta-analysis
- Population
- Adults and children with primary sleep disorders (insomnia, delayed sleep phase syndrome, REM sleep behaviour disorder) in placebo-controlled trials; primary outcome; fixed-effects pooled estimate, latency measured by polysomnography/actigraphy or by sleep diary depending on trial
Meta-analysis: melatonin for the treatment of primary sleep disorders.2013PMID:23691095
Decreases intensive care unit length of stay
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“However, melatonin group demonstrated significantly lower serum HMGB-1 and NT-pro-BNP concentrations along with shorter duration of MV and less need for oxygen therapy and shorter length of NICU stay compared to control group.”
Quoted verbatim from Melatonin effects on the left ventricular function in neonates with persistent pulmonary hypertension.. - Study
- RCT
- Dose
- Oral melatonin 10 mg/kg/day for five doses, started within the first 24 h; melatonin tablets crushed, suspended in 5 mL normal saline and given by orogastric tube, in addition to standard care
- Population
- Neonates of at least 36 weeks' gestation with persistent pulmonary hypertension of the newborn (PPHN), neonatal intensive care unit, Tanta University Hospitals, Egypt; n=80 randomised and analysed (40 melatonin plus standard care, 40 placebo plus standard care); NICU length of stay was a pre-specified SECONDARY clinical outcome (primary outcome was LV function at end of therapy, with LV-GLS the principal endpoint); open to clinicians, outcome assessors blinded
Melatonin effects on the left ventricular function in neonates with persistent pulmonary hypertension.2026PMID:41954764
Show the remaining 6
Increases HDL cholesterol
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“HDL-C levels were substantially increased (WMD: 2.04 mg/dL, 95% CI: 0.50, 3.57) following melatonin supplementation.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect 2.04 mean difference, 95% CI 0.5 to 3.57
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
Decreases glycated haemoglobin (HbA1c)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“Melatonin supplementation was associated with a statistically significant reduction in glycated hemoglobin (HbA1c) levels compared to placebo [mean difference [MD]: -0.65; 95% CI: -1.28, -0.02; P = 0.04]”
Quoted verbatim from The effect of melatonin supplementation on glycemic control in patients with type 2 diabetes.. - Study
- meta-analysis
- Participants
- 325
- Population
- adults with type 2 diabetes mellitus
The effect of melatonin supplementation on glycemic control in patients with type 2 diabetes.2025PMID:40698248
Decreases malondialdehyde (circulating)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“The reduction in serum MDA in the melatonin group was also statistically significant when compared to the placebo group ( P = 0.03; Table 3).”
Quoted verbatim from Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.. - Study
- RCT
- Dose
- Melatonin 5 mg tablet, one tablet nightly one hour before bedtime, for 10 weeks
- Population
- Adults aged 19-75 with chronic kidney failure on continuous ambulatory peritoneal dialysis, four PD centres in Iran; 46 recruited, 44 analysed (22 melatonin, 22 placebo) after one exclusion per group for peritonitis; serum MDA was a pre-specified PRIMARY outcome; double-blind, placebo-controlled; MDA measured in serum by colorimetric commercial kit (ZellBio GmbH), intra-assay CV 5.5%; between-group comparison of change from baseline at week 10
Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.2025PMID:41125682Industry funded
Decreases fasting blood glucose
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“The pooled analysis displayed that melatonin supplementation substantially lowered serum FBG levels in the melatonin group compared with the placebo group (WMD: −11.63 mg/dL, 95% CI: −19.16, −4.10).”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -11.63 mean difference, 95% CI -19.16 to -4.1
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
Decreases total cholesterol (TC)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“The meta-analysis indicated that melatonin supplementation significantly reduced serum TC (WMD: −6.97 mg/dL, 95% CI: −12.20, −1.74) and LDL-C levels (WMD: −6.28 mg/dL, 95% CI: −10.53, −2.03) in the melatonin group compared with the control group.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -6.97 mean difference, 95% CI -12.2 to -1.74
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
Decreases LDL cholesterol
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“The meta-analysis indicated that melatonin supplementation significantly reduced serum TC (WMD: −6.97 mg/dL, 95% CI: −12.20, −1.74) and LDL-C levels (WMD: −6.28 mg/dL, 95% CI: −10.53, −2.03) in the melatonin group compared with the control group.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -6.28 mean difference, 95% CI -10.53 to -2.03
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
What did not
17 findings
Measured, and no effect detected. These are findings, not gaps — a trial that looked and found nothing is the most easily lost result in this field.
No detected effect on all-cause mortality
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“We found no significant difference in mortality between patients receiving melatonin and those receiving placebo (RR, 0.90; 95% CI: 0.77–1.06; I2 = 0%).”
Quoted verbatim from Prophylactic melatonin for delirium in critically ill patients: A systematic review and meta-analysis with trial sequential analysis.. - Study
- meta-analysis
- Participants
- 2,350
- Population
- Adult ICU patients; secondary endpoint, 10 trials, longest reported follow-up
Effect 0.9 risk ratio, 95% CI 0.77 to 1.06
Prophylactic melatonin for delirium in critically ill patients: A systematic review and meta-analysis with trial sequential analysis.2022PMID:36316858
No detected effect on body mass index
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“The results of random-effect meta-analysis indicated that melatonin intake has no effect on weight (SMD: −0.03, 95% CI: −0.30, 0.25, I2 = 00.00%) and BMI (SMD: −0.03, 95% CI: −0.30, 0.25, I2 = 00.00%) in patients with PCOS (Fig..).”
Quoted verbatim from Effect of melatonin supplementation on cardiometabolic risk factors, oxidative stress and hormonal profile in PCOS patients: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Dose
- 3-10 mg/day oral
- Population
- women with polycystic ovary syndrome; 6 double-blind RCTs
Effect -0.03 standardised mean difference, 95% CI -0.3 to 0.25
No detected effect on C-reactive protein concentration
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“However, the summary effect of melatonin on CRP was not significant (−0.18; −0.91, 0.55; p=0.62).”
Quoted verbatim from Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials.. - Study
- meta-analysis
- Population
- Adults in placebo-controlled clinical trials of exogenous melatonin, mixed clinical populations
Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials.2021PMID:33581247
No detected effect on total leukocyte count
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“In the 3 studies, there was no significant difference in WBC count between the melatonin treated group and the control group (WMD = –1.07, 95% CI = –2.44, 0.30, P =.13) (Fig..”
Quoted verbatim from The safety and efficacy of melatonin in the treatment of COVID-19: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Hospitalised COVID-19 patients; secondary endpoint, 3 trials of adjunctive melatonin vs control
Effect -1.07 mean difference, 95% CI -2.44 to 0.3
The safety and efficacy of melatonin in the treatment of COVID-19: A systematic review and meta-analysis.2022PMID:36181086
No detected effect on total sleep time
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull resultreplicated ×2“The median in-hospital sleep duration was 6.0 hours (IQR: 5.0–6.2), with slightly longer duration in the melatonin group (6.0 (5.3–6.3) vs 5.8 (5.0–6.0), p=0.136), though this difference was not statistically significant.”
Quoted verbatim from Effect of melatonin versus placebo for the prevention of delirium among medically hospitalised older patients: a double-blinded randomised controlled trial (project RESTORE).. - Study
- RCT
- Duration
- 5 days
- Dose
- 5 mg or 8 mg oral melatonin nightly for up to 5 days (arms pooled)
- Population
- medically hospitalised patients aged 65 years and over; secondary endpoint, ITT; sleep duration from patient report and nursing observation, not polysomnography
No detected effect on serious adverse event incidence
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“In terms of safety, no serious adverse events were reported with either melatonin or placebo.”
Quoted verbatim from Effect of melatonin versus placebo for the prevention of delirium among medically hospitalised older patients: a double-blinded randomised controlled trial (project RESTORE).. - Study
- RCT
- Duration
- 5 days
- Dose
- 5 mg or 8 mg oral melatonin nightly for up to 5 days (arms pooled)
- Population
- medically hospitalised patients aged 65 years and over; safety endpoint, ITT
Show the remaining 11
No detected effect on diastolic blood pressure (setting unspecified)
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“Mean Daytime Diastolic Blood Pressure (DBP) (SECONDARY, mmHg) -- NCT01114360: Melatonin 85.7 +/-1.6 (n=36) vs Placebo 86.2 +/-1.7 (n=36); difference -0.5; p=0.89, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect -0.5 mean difference
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360
No detected effect on diastolic blood pressure (setting unspecified)
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“Mean Nighttime Diastolic Blood Pressure (DBP) (PRIMARY, mmHg) -- NCT01114360: Melatonin 76 +/-1.7 (n=36) vs Placebo 76.2 +/-1.8 (n=36); difference -0.2; p=0.75, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect -0.2 mean difference
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360
No detected effect on total sleep time
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×2“Total Sleep Time (SECONDARY, minutes) -- NCT01114360: Melatonin 399.8 +/-11.0 (n=36) vs Placebo 412.2 +/-11.1 (n=36); difference -12.4; p=0.52, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect -12.4 mean difference
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360
No detected effect on mean arterial pressure
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“Mean Daytime Mean Arterial Pressure (MAP) (SECONDARY, mmHg) -- NCT01114360: Melatonin 102.2 +/-1.7 (n=36) vs Placebo 102.1 +/-1.8 (n=36); difference 0.1; p=0.97, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect 0.1 mean difference
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360
No detected effect on mean arterial pressure
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“Mean Nighttime Mean Arterial Pressure (MAP) (SECONDARY, mmHg) -- NCT01114360: Melatonin 92.9 +/-1.9 (n=36) vs Placebo 92.6 +/-2.0 (n=36); difference 0.3; p=0.79, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect 0.3 mean difference
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360
No detected effect on mean arterial pressure
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“Mean Nighttime Mean Arterial Pressure (MAP) (SECONDARY, mmHg) -- NCT01114373: Melatonin 93.9 +/-1.8 (n=36) vs Placebo 94.4 +/-1.8 (n=36); difference -0.5; p=0.91, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect -0.5 mean difference
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study2015NCT01114373
No detected effect on systolic blood pressure (setting unspecified)
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“Mean Daytime Systolic Blood Pressure (SBP) (SECONDARY, mmHg) -- NCT01114373: Melatonin 134.2 +/-2.4 (n=36) vs Placebo 137.3 +/-2.4 (n=36); difference -3.1; p=0.16, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect -3.1 mean difference
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study2015NCT01114373
No detected effect on diastolic blood pressure (setting unspecified)
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“Mean Daytime Diastolic Blood Pressure (DBP) (SECONDARY, mmHg) -- NCT01114373: Melatonin 85.3 +/-1.8 (n=36) vs Placebo 86.6 +/-1.8 (n=36); difference -1.3; p=0.12, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect -1.3 mean difference
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study2015NCT01114373
No detected effect on mean arterial pressure
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“Mean Daytime Mean Arterial Pressure (MAP) (SECONDARY, mmHg) -- NCT01114373: Melatonin 101.26 +/-1.9 (n=36) vs Placebo 103.5 +/-1.9 (n=36); difference -2.24; p=0.12, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect -2.24 mean difference
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study2015NCT01114373
No detected effect on systolic blood pressure (setting unspecified)
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“Mean Daytime Systolic Blood Pressure (SBP) (SECONDARY, mmHg) -- NCT01114360: Melatonin 135.13 +/-2.2 (n=36) vs Placebo 133.9 +/-2.2 (n=36); difference 1.23; p=0.64, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect 1.23 mean difference
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360
No detected effect on total sleep time
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×2“Total Sleep Time (SECONDARY, minutes) -- NCT01114373: Melatonin 415.8 +/-10.9 (n=36) vs Placebo 413.4 +/-10.6 (n=36); difference 2.4; p=0.39, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study. - Study
- crossover
- Participants
- 72
- Population
- Hypertension; 18 Years+
Effect 2.4 mean difference
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study2015NCT01114373
What it touches on the way
A finding says melatonin moved an endpoint. This is the biology in between: the proteins and reactions it runs through to get there. It is where to look for the two things a list of findings cannot answer — why a result might happen, and what else acts on the same machinery.
1 of these are proteins with a page of their own, and that is the door: a protein page says what else it carries, which is how one compound leads to the next.
Mechanistic reach
1 entity
1 entities reached, most connected first. Hub metabolites are excluded, so this is not a claim that the compound touches everything.
0 reported hop1 assembled from the scaffold